The Highs and Lows of Biotech Mergers: What Werewolf Therapeutics' Stock Surge Reveals The recent 100% surge in Werewolf Therapeutics' stock is a striking example of how biotech mergers can send shockwaves through the market.
Behind this explosive growth lies access to late stage research, substantial funding, and potentially game changing treatments for Complex Regional Pain Syndrome Type 1 (CRPS 1).
The Allure of Ambros' Research Werewolf Therapeutics is gaining access to Ambros' neridronate program, a treatment being developed as a potential solution for CRPS 1.